oxocan-2-one | 539-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: oxocan-2-one
• 英文别名: heptanolactone；2-oxocanone
• CAS: 539-87-7
• 化学式: C₇H₁₂O₂
• 分子量: 128.171
• InChiKey: BTLSLHNLDQCWKS-UHFFFAOYSA-N

物化性质

• 沸点：
  70 °C(Press: 5 Torr)
• 密度：
  0.989±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2932209090

反应信息

• 作为反应物：
  描述：

  oxocan-2-one 在 三乙基硼氢化锂 作用下， 以 various solvent(s) 为溶剂， 反应 0.42h， 生成 正庚醇
  参考文献：
  名称：

  Lactones. 2. Enthalpies of hydrolysis, reduction, and formation of the C4-C13 monocyclic lactones. Strain energies and conformations

  摘要：

  The enthalpies of hydrolysis of the monocyclic lactones from gamma-butyrolactone to tridecanolactone were determined calorimetrically, and the acyclic ethyl esters having the same number of atoms were studied in the same fashion. The enthalpies of reduction of the lactones to the corresponding alpha,omega-alkanediols with lithium triethylborohydride also were determined. The enthalpies of formation of the lactones and the ethyl esters were derived from these data. They were converted to values for the gas phase by measuring the enthalpies of vaporization of ethyl esters and of lactones. In the cases of gamma-butyrolactone and delta-valerolactone, the enthalpies of formation were in good accord with the previously reported values determined via combustion calorimetry. The strain energies of the lactones were obtained via isodesmic reactions. Valerolactone had a strain energy of 11 kcal/mol, and the largest strain energy was found with octanolactone (13 kcal/mol). The conformations of gamma-butyrolactone and delta-valerolactone were studied via MP2/6-31G* geometry optimizations, and the conformations of the other lactones were studied with use of the molecular mechanics program MM3. The energies of the lactones estimated via molecular mechanics were compared with the experimental results.

  DOI：

  10.1021/ja00020a036
• 作为产物：
  描述：

  环庚酮 在 氧气 、 苯甲醛 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 oxocan-2-one
  参考文献：
  名称：

  协同效应增强树脂衍生碳负载 FeCe 双金属催化剂的 Baeyer-Villiger 氧化性能

  摘要：

  得益于负载双金属CeFe诱导更高的金属分散性和更高的活性氧含量的协同效应，以及树脂衍生碳对自由基的缓冲作用，环己酮有氧氧化为ε-己内酯（ε-CL）与CeFe@RDC-x相比，催化效率显着提高。特别是当使用无溶剂且绿色溶剂（如乙酸乙酯）时，可以实现优异的催化转化效果。

  DOI：

  10.1002/cctc.202300852

文献信息

• Thionation with the Reagent Combination of Phosphorus Pentasulfide and Hexamethyldisiloxane
  作者：Thomas J. Curphey

  DOI：10.1021/jo0256742

  日期：2002.9.1

  The combination of P4S10 and hexamethyldisiloxane efficiently converts esters, lactones, amides, lactams, and ketones to their corresponding thiono derivatives. In the presence of elemental sulfur, 3-oxoesters are converted to dithiolethiones by this reagent. Yields are comparable to or superior to those obtained with Lawesson's reagent. The method has the advantage that reagent-derived byproducts

  P4S10和六甲基二硅氧烷的组合可将酯，内酯，酰胺，内酰胺和酮有效地转化为其相应的硫代衍生物。在元素硫的存在下，该试剂将3-氧代酯转化为二硫代硫酮。产率与使用劳森试剂获得的产率相当或更高。该方法的优点在于，可以通过简单的水解后处理或通过硅胶过滤而不是通过劳氏试剂所要求的色谱法来除去试剂衍生的副产物。
• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES D'INHIBITEURS DE JAK ET LEURS UTILISATIONS
  申请人：PURETECH LYT INC

  公开号：WO2020176859A1

  公开（公告）日：2020-09-03

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其药物组成物，生产这种前药和组成物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或状况的方法，例如本文所披露的那些，包括向需要的患者施用所披露的脂质前药或其药物组成物。
• Scandium Trifluoromethanesulfonate as an Extremely Active Lewis Acid Catalyst in Acylation of Alcohols with Acid Anhydrides and Mixed Anhydrides
  作者：Kazuaki Ishihara、Manabu Kubota、Hideki Kurihara、Hisashi Yamamoto

  DOI：10.1021/jo952237x

  日期：1996.1.1

  is commercially available, is a practical and useful Lewis acid catalyst for acylation of alcohols with acid anhydrides or the esterification of alcohols by carboxylic acids in the presence of p-nitrobenzoic anhydrides. The remarkably high catalytic activity of scandium triflate can be used for assisting the acylation by acid anhydrides of not only primary alcohols but also sterically-hindered secondary

  可商购的三氟甲磺酸（三氟甲磺酸late）是一种实用且有用的路易斯酸催化剂，用于在对硝基苯甲酸酐的存在下将醇与酸酐酰化或将醇通过羧酸酯化。三氟甲磺酸scan的极高的催化活性可用于协助伯醇的酸酐酰化以及空间受阻的仲或叔醇的酸酐酰化。所提出的方法对于ω-羟基羧酸的选择性大内酯化特别有效。
• Indazole-derivatives as factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1479675A1

  公开（公告）日：2004-11-24

  The present invention relates to compounds of the formulae I and Ib wherein R0 ; R1 ; R2 ;Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ib, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I和Ib的化合物 其中R0; R1; R2; Q; V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝块酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于因子Xa和/或因子VIIa的不良活性存在或因子Xa和/或因子VIIa的抑制而打算治愈或预防的情况。此外，本发明还涉及制备式I和Ib的化合物的方法，它们的用途，特别是作为药物中的活性成分，并包括它们的制药制剂。